Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2017.049 | A phase Ib study of PDR001 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2014.357 | A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) ADMINISTERED WITH ERLOTINIB OR ALECTINIB IN PATIENTS WITH ADVANCED NON−SMALL CELL LUNG CANCER | Prof. MA Brigette Buig Yue |
| 2013.392 | A phase Ib trial of LEE011 in combination with everolimus (RAD001) and exemestane in the treatment of postmenopausal women with hormone receptor positive HER2 negative locally advanced or metastatic breast cancer | Prof. MA Brigette Buig Yue |
| 2018.436 | A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select immunotherapy combinations in adult patients with triple negative breast cancer |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2018.553 | A phase Ib, open label, multi-center study to characterize the safety, tolerability and preliminary efficacy of EGF816 in combination with selected targeted agents in EGFR mutant NSCLC |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2017.452 | A Phase Ib, Open Label, Multiple Ascending Dose, Pilot Study to Assess the Safety, Preliminary Efficacy and Pharmacokinetics of Subcutaneously Administered APL-2 in Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH). – PADDOCK – |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2019.327 | A Phase Ib, open-label, multi-center study to characterize the safety, tolerability, and preliminary efficacy of TNO155 in combination with spartalizumab or ribociclib in selected malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2020.626 | A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2019.652 | A phase Ib/II, multicenter open-label study of CS1001 in combination with regorafenib in patients with advanced or refractory solid tumors | Dr. LOONG Herbert Ho Fung |
| 2015.389 | A Phase Ib/II, Multicentre, Open Label, Randomised Study of BI 836845 in Combination with Enzalutamide, versus Enzalutamide alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abiraterone |
Dr. HO Wing Ming 何永明醫生 |
| 2017.357 | A Phase Ib/II, open label, multicenter study of MCS110 in combination with PDR001 in patients with advanced malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2013.294 | A phase Ib/II, open-label study of LJM716 in combination with BYL719 compared to taxane or irinotecan in patients with previously treated esophageal squamous cell carcinoma | Prof. MA Brigette Buig Yue |
| 2016.172 | A phase Ib/II, open-label, multi-center study of INC280 in combination with PDR001 or PDR001 single agent in advanced hepatocellular carcinoma |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2019.352 | A Phase Ib/IIa, Single Ascending Dose Study of the Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients with Type 2 Diabetes Mellitus | Dr. CHOW Elaine Yee Kwan |
| 2020.445 | A Phase II CCCG-ALL Multi-center Trial of Dasatinib in Combination with Intensive Induction Therapy for Children with First Relapsed T-cell Acute Lymphoblastic Leukemia |
Prof. LI Chi Kong 李志光 |
| 2023.684 | A phase II clinical study to evaluate the safety, efficacy, and pharmacokinetics of RBD1016 injection in participants with chronic hepatitis B | Prof. WONG Grace Lai Hung |
| 2019.694 | A phase II clinical trial to study the efficacy of cabozantinib in patients with hepatocellular carcinoma refractory to checkpoint inhibitors |
Dr. CHAN Stephen Lam 陳林 |
| 2005.020 | A Phase II Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Dose-Ranging, Parallel Group Study of the Safety and Efficacy of The Oral Neurokinin-1 Receptor Antagonist, GW679769 When Administered as a Daily Doses of 50mg, 100mg and 150mg Oral Tablets in Combination with Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly Emetogenic Cisplatin-based Chemotherapy | Prof. Yeo Winnie |
| 2015.002 | A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases treated with hormonal treatment background therapy | Dr. SUEN Joyce |
| 2008.092 | A Phase II Safety and Efficacy Study with the VEGF Receptor Tyrosine Kinase Inhibitor GW786034 in Patients with Metastatic Urothelial Cancer | Dr HO Wing Ming |
| 2008.512 | A Phase II Single Arm, Multi-Centre Study of Bevacizumab (Avastin_) Pre- and Post- Transarterial Chemoembolisation (TACE) Treatment for Localised Unresectable Hepatocellular Carcinoma (HCC) | Prof. Lai Bo San Paul |
| 2005.416 | A Phase II Study of Concurrent Cetuximab, Cisplatin and Radiotherapy in the Treatment of Advanced Nasopharyngeal Carcinoma | Prof. Ma Buig Yue Brigette |
| 2007.198 | A Phase II Study of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3D-CRT) or Intensity-Modulated Radiation Therapy (IMRT) + Bevacizumab (BV) for Locally or Regionally Advanced Nasopharyngeal Cancer | Prof. CHAN Anthony T. C. |
| 2008.141 | A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer | Prof. MA Brigette |
| 2005.408 | A Phase II Study of Hormonal Therapy and Docetaxel and Prednisolone in Patients with Hormone-Treatment Na_ve Metastatic Prostate Adenocarcinoma | Dr. Ng Chi Fai |
| 2011.176 | A phase II study of orally administered BEZ235 monotherapy in patients with hormone receptor positive, HER2 negative, metastatic breast cancer, with or without PI3K activated pathway | Dr. Ho Wing Ming |
| 2002.155 | A Phase II Study of Sequential Administration of Irinotecan and Cisplatin Combination Followed by Docetaxel in Treatment of Advanced Non-small Cell Lung Cancer | Prof. Mok Tony |
| 2008.125 | A Phase II Study of Stereotactic Body Radiation Therapy (SBRT) under Active Breathing Control for Primary Lung Cancer and Lung Metastases | Dr. Tsang Wai Kong |
| 2002.169 | A Phase II Study Of The Efficacy And Safety of Irinotecan in Combination With Capecitabine As First Line Chemotherapy in Asia Subjects With Inoperable Hepatocellular Carcinoma | Dr. Mok Tony |
| 2010.359 | A Phase II Study of Transarterial Chemoembolization and Axitinib for the Treatment of Unresectable Hepatocellular Carcinoma | Prof. CHAN Stephen Lam |
| 2003.352 | A Phase II Study of Triapine and Gemcitabine as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer in Patients who had Prior Gemcitabine with Evaluation of the Effect of Triapine_ on Gemcitabine Pharmacokinetics and Cellular Uptake in Peripheral Mononuclear Cells | Prof. Ma Buig Yue Brigette |
| 2008.410 | A Phase II Study on the Therapeutics Effects of Acupuncture for Neurogenic Dysphagia | Ms Chan Sze Ling |
| 2009.010 | A Phase II Study to Evaluate the Effectiveness of Acupuncture in Treating Chemotherapy Induced Peripheral Neuropathy (CIPN) | Professor Mok Tony |
| 2006.149 | A Phase II Trial of 17-Allylamiogeldanamycin (17AAG) in Advanced Medullary and Differentitated Thyroid Carcinoma | MA Buig Yue Brigette |
| 2010.422 | A Phase II trial of BAY 86-9766 plus sorafenib as a first line systemic treatment for hepatocellular carcinoma (HCC) | Prof. Yeo Winnie |
| 2013.159 | A phase II trial of neoadjuvant imatinib for large gastric GIST in Asia | Professor Ng Enders Kwok Wai |
| 2013.338 | A phase II trial of PEG-BCT-100 as the second-line therapy following sorafenib in patients with advanced hepatocellular carcinoma | Dr. CHAN Stephen Lam |
| 2007.367 | A Phase II Trial of Sunitinib (SU11248) in Multiple Myeloma | Prof. Chan T.C. Anthony |
| 2006.215 | A Phase II Trial of VELCADE in Patients with Metastatic or Locally Recurrent Nasopharyngeal Carcinoma | MA Brigette |
| 2008.041 | A Phase II, Double-blind, Placebo-controlled, Dose-finding Study in Patients with Diabetic Neuropathic Pain to Evaluate Efficacy and Safety of TAK-583 | Dr Ozaki Risa |
| 2007.099 | A Phase II, Multicenter, Randomized, Double-Mask, Double-Dummy Study Comparing the Efficacy and Safety of Peramivir Administered Intravenously Once Daily Versus Oseltamivir Administered Orally Twice Daily in Adults with Acute Serious or Potentially Life-Threatening Influenza | Prof. Hui SC HUI |
| 2013.572 | A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF ATEZOLIZUMAB IN PATIENTS WITH PD-L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER | Prof. MOK Tony Shu Kam |
| 2012.422 | A phase II, multicenter, single-arm study of oral LDK378 in adult patients with ALK-activated non-small cell lung cancer previously treated with chemotherapy and crizotinib | Prof. MOK Tony Shu Kam |
| 2013.001 | A Phase II, open label, single arm, multicenter study of INC280 administered orally in adult patients with advanced hepatocellular carcinoma | Prof. CHAN Stephen Lam |
| 2014.257 | A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Patients with Locally Advanced/Metastatic Non Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours are Epidermal Growth Factor Receptor Mutation and T790M Mutation Positive (AURA2) | Prof. MOK Tony |
| 2008.470 | A Phase II, Open-Label, Cross-Sectional, Study to Compare eZscan, with Standard Methods of Screening for Diabetic Nephropathy, As a Tool for Detection of Type 2 Diabetic Nephropathy | Dr. Ozaki Risa |
| 2023.103 | A Phase II, Open-Label, Multi-Drug, Multi-Centre, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary) Sub-study 1: Hepatocellular Carcinoma (HCC) | Prof. CHAN Stephen Lam |
| 2023.376 | A Phase II, Open-Label, Multi-Drug, Multi-Centre, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary) Sub-study 2: Biliary Tract Cancer (BTC) | Prof. CHAN Stephan Lam |
| 2017.178 | A phase II, open-label, non-controlled, intra-patient dose escalation study to characterize the pharmacokinetics after oral administration of eltrombopag in pediatric patients with refractory, relapsed or treatment naïve severe aplastic anemia or recurrent aplastic anemia |
Prof. LI Chi Kong 李志光教授 |
| 2015.455 | A phase II, open-label, randomized controlled study of PDR001 in patients with moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma who progressed on standard treatment |
Prof. MA Brigette Buig Yue 馬碧如教授 |
Page 21 of 253.